Evidence map›Paper›PMID 36644322›Full record

ArticlePulmonary circulation2023

Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview.

Ayedh K Alamri, Nicholas J Shelburne, Jennalyn D Mayeux, Evan Brittain

Open access · goldAbstract read
In one paragraph

Article in Pulmonary circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Ayedh K AlamriDepartment of Medicine University of Utah Salt Lake City Utah USA.ORCID https://orcid.org/0000-0003-1424-0243
Nicholas J ShelburneDivision of Allergy, Pulmonary, and Critical Care Medicine Vanderbilt University Medical Center Nashville Tennessee USA.ORCID https://orcid.org/0000-0003-3008-9555
Jennalyn D MayeuxDepartment of Medicine, Division of Pulmonary and Critical Care Medicine University of Utah Salt Lake City Utah USA.
Evan BrittainDivision of Cardiovascular Medicine Vanderbilt University Medical Center Nashville Tennessee USA.
Vanderbilt University Medical Center · USNorthern Border University · SAUniversity of Utah · US

Funding

Interdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3M
NHLBI NIH HHS T32 HL094296
6 · The paper itself

Abstract

The considerable progress made in recent years in the diagnosis, risk stratification, and treatment of pulmonary hypertension was highlighted during the most recent edition of the Pulmonary Hypertension Association Scientific Sessions, which was held in Atlanta, Georgia from June 9 to 11, 2022, with the theme: Vision for the PHuture: The Evolving Science and Management of PH. Content presented over the 3-day conference focused on scientific and management updates since the last sessions were held in 2018 and included didactic talks, debates, and roundtable discussions across a broad spectrum of topics related to pulmonary hypertension. This article aims to summarize the key messages from each of the session talks.

Indexed as

Clinical Trials as topicpulmonary hypertensionPulmonary Hypertension Associationregistries

Identifiers

PMID36644322
PMCPMC9832865
OpenAlexW4312199326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.